Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Cancer
    April 2024
  1. JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al
    Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
    Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
    >> Share

  2. LOKE J, Labopin M, Craddock C, Socie G, et al
    Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party
    Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
    >> Share

  3. WANG X, Zhang B, Zhang Q, Zhou H, et al
    Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35316.
    >> Share

    March 2024
  4. DUFFY C, Hunger SP, Bhakta N, Denburg AE, et al
    Curing pediatric cancer: A global view. Examples from acute lymphoblastic leukemia.
    Cancer. 2024 Mar 29. doi: 10.1002/cncr.35290.
    >> Share

  5. HUANG R, He H, Xu X, Lin X, et al
    Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
    >> Share

  6. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    >> Share

    February 2024
  7. DINH A, Savoy JM, Kontoyiannis DP, Takahashi K, et al
    Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35251.
    >> Share

  8. GUAN F, Yang L, Chen Y, Shi J, et al
    Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
    Cancer. 2024 Feb 5. doi: 10.1002/cncr.35232.
    >> Share

    January 2024
  9. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    >> Share

    December 2023
  10. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
    Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
    Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
    >> Share

    November 2023
  11. YANG X, Yang L, Luo A, Liu S, et al
    IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35129.
    >> Share

  12. RUIZ J, Li Y, Cao L, Huang YV, et al
    Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35109.
    >> Share

  13. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    >> Share

    October 2023
  14. PULLARKAT V, Chen LS, Palmer J, Zhang J, et al
    A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35077.
    >> Share

  15. GUPTA DG, Varma N, Abdulkadir SA, Sreedharanunni S, et al
    A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Cancer. 2023 Oct 11. doi: 10.1002/cncr.35051.
    >> Share

  16. EFFICACE F, Cottone F, Yanez B, Kota V, et al
    Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
    Cancer. 2023 Oct 6. doi: 10.1002/cncr.35021.
    >> Share

    September 2023
  17. SASAKI K, Haddad FG, Short NJ, Jain N, et al
    Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
    Cancer. 2023 Sep 28. doi: 10.1002/cncr.35038.
    >> Share

  18. NIERENGARTEN MB
    Children living in extreme poverty face a greater risk of acute lymphoblastic leukemia relapse.
    Cancer. 2023;129:2764.
    >> Share

  19. GIEBEL S, Labopin M, Salmenniemi U, Socie G, et al
    Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the
    Cancer. 2023 Sep 1. doi: 10.1002/cncr.35004.
    >> Share

    August 2023
  20. BROWN JC, Ma C, Shi Q, Zemla T, et al
    Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).
    Cancer. 2023 Aug 31. doi: 10.1002/cncr.35007.
    >> Share

  21. TIBES R, Kosiorek HE, Dueck AC, Palmer J, et al
    Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
    Cancer. 2023;129:2321-2330.
    >> Share

    July 2023
  22. GUPTA DG, Varma N, Sharma P, Truica MI, et al
    Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
    Cancer. 2023 Jul 27. doi: 10.1002/cncr.34957.
    >> Share

  23. NUHOGLU KANTARCI E, Tolgay E, Eskazan AE
    Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient.
    Cancer. 2023 Jul 3. doi: 10.1002/cncr.34938.
    >> Share

  24. MA YY, Wei ZL, Xu YJ, Shi JM, et al
    Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study.
    Cancer. 2023;129:2013-2022.
    >> Share

    June 2023
  25. TIRIBELLI M, Latagliata R, Breccia M, Capodanno I, et al
    Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
    Cancer. 2023 Jun 24. doi: 10.1002/cncr.34923.
    >> Share

  26. VENUGOPAL S, Taylor J
    Trying to outRun-DIC in KMT2Ar AML: It's tricky.
    Cancer. 2023;129:1797-1799.
    >> Share

  27. AL HAMED R, Ngoya M, Galimard JE, Sengeloev H, et al
    Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
    Cancer. 2023 Jun 2. doi: 10.1002/cncr.34843.
    >> Share

    May 2023
  28. LIAO H, Xu Y, Meng Q, Mao Z, et al
    A convolutional neural network-based, quantitative complete blood count scattergram-mapping framework promptly screens acute promyelocytic leukemia with high sensitivity.
    Cancer. 2023 May 31. doi: 10.1002/cncr.34890.
    >> Share

  29. FRANCO S, Geng X, Korostyshevskiy V, Karp JE, et al
    Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia.
    Cancer. 2023 May 31. doi: 10.1002/cncr.34894.
    >> Share

  30. NIERENGARTEN MB
    Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:1466.
    >> Share

  31. HADDAD FG, Bidikian A, Issa GC
    Reply to "Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!".
    Cancer. 2023 May 3. doi: 10.1002/cncr.34834.
    >> Share

  32. ESKAZAN AE
    Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!
    Cancer. 2023 May 3. doi: 10.1002/cncr.34833.
    >> Share

    April 2023
  33. FORAN JM, Sun Z, Lai C, Fernandez HF, et al
    Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34807.
    >> Share

  34. DUONG VH, Ruppert AS, Mims AS, Borate U, et al
    Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
    Cancer. 2023 Apr 20. doi: 10.1002/cncr.34780.
    >> Share

  35. GORDON MJ, Jones JE, George B, Peterson C, et al
    Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
    Cancer. 2023 Apr 5. doi: 10.1002/cncr.34787.
    >> Share

    March 2023
  36. CHRISTAKOPOULOS GE, Walker KN, Smith J, Takemoto CM, et al
    Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods.
    Cancer. 2023 Mar 21. doi: 10.1002/cncr.34751.
    >> Share

  37. ZHANG H, Wan Y, Wang H, Cai J, et al
    Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.
    Cancer. 2023 Mar 21. doi: 10.1002/cncr.34741.
    >> Share

  38. NGUYEN D, Kantarjian HM, Short NJ, Qiao W, et al
    Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
    Cancer. 2023 Mar 9. doi: 10.1002/cncr.34728.
    >> Share

  39. HADDAD FG, Kantarjian HM, Bidikian A, Jabbour EJ, et al
    Association between bariatric surgery and outcomes in chronic myeloid leukemia.
    Cancer. 2023 Mar 7. doi: 10.1002/cncr.34725.
    >> Share

  40. XIE M, Shi T, Jiang Q, Jia Y, et al
    Chemotherapy with the use of next-generation TKIs based on MRD has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Cancer. 2023 Mar 7. doi: 10.1002/cncr.34710.
    >> Share

    February 2023
  41. LOGAN AC
    Lower leukemia burden maximizes the impact of blinatumomab therapy.
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34666.
    >> Share

  42. QUEUDEVILLE M, Stein AS, Locatelli F, Ebinger M, et al
    Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34667.
    >> Share

  43. CASTELLANOS MI, Oluyomi AO, Chambers TM, Gramatges MM, et al
    Ethnic disparities in childhood leukemia survival by border residence: A Texas population-based analysis.
    Cancer. 2023 Feb 21. doi: 10.1002/cncr.34636.
    >> Share

  44. ARISTIZABAL P, Thornburg CD, Young J
    At the border: A call to action for health equity for children with leukemia.
    Cancer. 2023 Feb 21. doi: 10.1002/cncr.34629.
    >> Share

  45. NIERENGARTEN MB
    Poorer outcomes in young adult Black patients with acute myeloid leukemia.
    Cancer. 2023;129:493.
    >> Share

  46. BODDU PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, et al
    A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Cancer. 2023;129:580-589.
    >> Share

  47. GUPTA DG, Varma N, Kumar A, Naseem S, et al
    Genomic and proteomic characterization of Philadelphia-like B-lineage acute lymphoblastic leukemia: A report of Indian patients.
    Cancer. 2023 Feb 3. doi: 10.1002/cncr.34665.
    >> Share


  48. Off-the-shelf T cells deliver remissions for certain kinds of leukemia.
    Cancer. 2023;129:332.
    >> Share

    January 2023
  49. SASAKI K, Ravandi F, Kadia TM, Borthakur G, et al
    Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
    Cancer. 2023 Jan 30. doi: 10.1002/cncr.34609.
    >> Share

  50. WONG CI, Vannatta K, Gilleland Marchak J, Quade EV, et al
    Preventable harm because of outpatient medication errors among children with leukemia and lymphoma: A multisite longitudinal assessment.
    Cancer. 2023 Jan 27. doi: 10.1002/cncr.34651.
    >> Share

  51. HARRIS RD, Bernhardt MB, Zobeck MC, Taylor OA, et al
    Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34646.
    >> Share

  52. TODISCO E, Papayannidis C, Fracchiolla N, Petracci E, et al
    AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34608.
    >> Share

  53. EL-JAWAHRI A, Luskin MR, Greer JA, Traeger L, et al
    Psychological mobile app for patients with acute myeloid leukemia (AML): A pilot randomized clinical trial.
    Cancer. 2023 Jan 18. doi: 10.1002/cncr.34645.
    >> Share

  54. PORTUGUESE AJ, Albittar A, Gooley TH, Deeg HJ, et al
    Transplantation for myeloid neoplasms with antecedent solid tumor.
    Cancer. 2023;129:142-150.
    >> Share

    December 2022
  55. KENT A, Pollyea DA
    Top advances of the year: Leukemia.
    Cancer. 2022 Dec 30. doi: 10.1002/cncr.34619.
    >> Share

  56. SHUAI W, Zuo Z, Li N, Garces S, et al
    ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
    Cancer. 2022 Dec 29. doi: 10.1002/cncr.34616.
    >> Share

  57. BADAR T, Litzow MR, Shallis RM, Patel A, et al
    Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
    Cancer. 2022 Dec 21. doi: 10.1002/cncr.34604.
    >> Share

  58. YU CH, Jou ST, Su YH, Coustan-Smith E, et al
    Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
    Cancer. 2022 Dec 20. doi: 10.1002/cncr.34606.
    >> Share

  59. ESPINOZA D, Blanco Lopez JG, Vasquez R, Fu L, et al
    How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience.
    Cancer. 2022 Dec 12. doi: 10.1002/cncr.34572.
    >> Share

  60. CHENG F, Zeng F, Li Q, Cui Z, et al
    Reply to "Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!".
    Cancer. 2022 Dec 8. doi: 10.1002/cncr.34578.
    >> Share

  61. ESKAZAN AE
    Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!
    Cancer. 2022 Dec 8. doi: 10.1002/cncr.34577.
    >> Share

  62. ZENG Z, Maiti A, Herbrich S, Cai T, et al
    Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
    Cancer. 2022 Dec 7. doi: 10.1002/cncr.34566.
    >> Share

  63. BAZINET A, Darbaniyan F, Kadia TM, Venugopal S, et al
    A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
    Cancer. 2022 Dec 2. doi: 10.1002/cncr.34564.
    >> Share

    November 2022
  64. DUDLEY IM, Sunguc C, Heymer EJ, Winter DL, et al
    Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study.
    Cancer. 2022 Nov 29. doi: 10.1002/cncr.34561.
    >> Share

  65. SHALLIS RM, Daver NG, Altman JK, Hasserjian RP, et al
    TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
    Cancer. 2022 Nov 17. doi: 10.1002/cncr.34535.
    >> Share

  66. HAN H, Yao Y, Wang H, Zhou M, et al
    Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34534.
    >> Share

  67. ORGEL E, Mittelman SD
    From soup to nuts: Obesity impairs chemotherapy during early and late phases of acute lymphoblastic leukemia treatment.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34528.
    >> Share

  68. WADHWA A, Chen Y, Hageman L, Hoppmann AL, et al
    Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: A Children's Oncology Group report.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34529.
    >> Share

  69. LIPSKY AH, Lamanna N
    Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
    Cancer. 2022 Nov 3. doi: 10.1002/cncr.34510.
    >> Share

  70. HA H, Kim HJ, Park JH, Shin A, et al
    Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: A Korean nationwide study.
    Cancer. 2022;128:3888-3896.
    >> Share

    October 2022
  71. YE MT, Wang Y, Zuo Z, Calin S, et al
    Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia.
    Cancer. 2022 Oct 25. doi: 10.1002/cncr.34515.
    >> Share

  72. PASTORE F, Pastore A, Rothenberg-Thurley M, Metzeler KH, et al
    Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis.
    Cancer. 2022 Oct 22. doi: 10.1002/cncr.34495.
    >> Share

  73. PATEL PA, DeGroote NP, Jackson K, Cash T, et al
    Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia.
    Cancer. 2022 Oct 13. doi: 10.1002/cncr.34476.
    >> Share

  74. JIA R, Ji M, Li G, Xia Y, et al
    Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy.
    Cancer. 2022 Oct 5. doi: 10.1002/cncr.34481.
    >> Share

  75. CHENG F, Zeng F, Li Q, Cui Z, et al
    Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia.
    Cancer. 2022 Oct 1. doi: 10.1002/cncr.34478.
    >> Share

    September 2022
  76. NAGLER A, Labopin M, Arat M, Remenyi P, et al
    Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelat
    Cancer. 2022 Sep 15. doi: 10.1002/cncr.34452.
    >> Share

  77. BALL S, Knepper TC, Deutsch YE, Samra W, et al
    Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
    Cancer. 2022 Sep 15. doi: 10.1002/cncr.34459.
    >> Share

    July 2022
  78. ALVAREZ-LARRAN A, Garrote M, Ferrer-Marin F, Perez-Encinas M, et al
    Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Cancer. 2022;128:2441-2448.
    >> Share

    June 2022
  79. KENNEDY KR, Turner JH, MacDonald WBG, Claringbold PG, et al
    Long-term survival and toxicity in patients with neuroendocrine tumors treated with (177) Lu-octreotate peptide radionuclide therapy.
    Cancer. 2022;128:2182-2192.
    >> Share

    May 2022
  80. LOKE J, Labopin M, Craddock C, Cornelissen JJ, et al
    Additional cytogenetic features determines outcome in patients allografted for TP53 mutant acute myeloid leukemia.
    Cancer. 2022 May 25. doi: 10.1002/cncr.34268.
    >> Share

    April 2022
  81. SHESHADRI A, Goizueta AA, Shannon VR, London D, et al
    Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
    Cancer. 2022 Apr 22. doi: 10.1002/cncr.34229.
    >> Share

  82. DINARDO CD, Garcia-Manero G, Kantarjian HM
    Time to blur the blast boundaries.
    Cancer. 2022;128:1568-1570.
    >> Share

  83. O'ROURKE K
    CD123 expression linked to high-risk disease in children with acute myeloid leukemia.
    Cancer. 2022;128:1357-1358.
    >> Share

    March 2022
  84. CHEN X, Huang J, Xu N, Fan Z, et al
    A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
    Cancer. 2022 Mar 22. doi: 10.1002/cncr.34182.
    >> Share

    February 2022
  85. CONTER V, Schrappe M, Escherich G
    Does the Y chromosome play a role for outcome in childhood acute lymphoblastic leukemia?
    Cancer. 2022 Feb 24. doi: 10.1002/cncr.34147.
    >> Share

  86. GUPTA S, Teachey DT, Chen Z, Rabin KR, et al
    Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.
    Cancer. 2022 Feb 24. doi: 10.1002/cncr.34150.
    >> Share

  87. CHOW EJ, Aplenc R, Vrooman LM, Doody DR, et al
    Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
    Cancer. 2022;128:788-796.
    >> Share

  88. O'ROURKE K
    Study examines oral health of patients with leukemia.
    Cancer. 2022;128:430-431.
    >> Share

    December 2021
  89. GARCIA KA, Cherian S, Stevenson PA, Martino CH, et al
    Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
    Cancer. 2021 Dec 21. doi: 10.1002/cncr.34073.
    >> Share

  90. UNGER JM, Beauchemin M, Hershman DL
    Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.
    Cancer. 2021;127:4574-4584.
    >> Share

    November 2021
  91. GUPTA S, Sutradhar R, Pequeno P, Hitzler JK, et al
    Risks of late mortality and morbidity among survivors of childhood acute leukemia with Down syndrome: A population-based cohort study.
    Cancer. 2021 Nov 30. doi: 10.1002/cncr.34042.
    >> Share

    October 2021
  92. NIERENGARTEN MB
    Higher mortality risk in African American women with triple-negative breast cancer.
    Cancer. 2021;127:3712-3713.
    >> Share

  93. CHEMAITILLY W, Li Z, Brinkman TM, Delaney A, et al
    Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences.
    Cancer. 2021 Oct 13. doi: 10.1002/cncr.33969.
    >> Share

  94. ALDOSS I, Otoukesh S, Zhang J, Mokhtari S, et al
    Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
    Cancer. 2021 Oct 11. doi: 10.1002/cncr.33967.
    >> Share

  95. KANTARJIAN HM, Jain N, Garcia-Manero G, Welch MA, et al
    The cure of leukemia through the optimist's prism.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33933.
    >> Share

    September 2021
  96. JAMY OH, Dhir A, Costa LJ, Xavier AC, et al
    Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
    Cancer. 2021 Sep 8. doi: 10.1002/cncr.33914.
    >> Share

    August 2021
  97. NELSON AM, Amonoo HL, Kavanaugh AR, Webb JA, et al
    Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial.
    Cancer. 2021 Aug 30. doi: 10.1002/cncr.33886.
    >> Share

  98. KENNEDY VE, Keegan THM, Li Q, Maguire FB, et al
    Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.
    Cancer. 2021 Aug 26. doi: 10.1002/cncr.33873.
    >> Share

  99. KANTARJIAN HM, Begna KH, Altman JK, Goldberg SL, et al
    Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33828.
    >> Share

  100. KLISOVIC RB, Leung WH, Brugger W, Dirnberger-Hertweck M, et al
    A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
    Cancer. 2021 Aug 3. doi: 10.1002/cncr.33796.
    >> Share

  101. MAITI A, DiNardo CD, Qiao W, Kadia TM, et al
    Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2021 Aug 3. doi: 10.1002/cncr.33814.
    >> Share

    July 2021

  102. Erratum to "Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL113
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33597.
    >> Share

  103. KIM K, Maiti A, Loghavi S, Pourebrahim R, et al
    Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33689.
    >> Share

    June 2021
  104. VENUGOPAL S, Shoukier M, Konopleva M, Dinardo CD, et al
    Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.
    >> Share

  105. SAXENA K, Herbrich SM, Pemmaraju N, Kadia TM, et al
    A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
    Cancer. 2021 Jun 25. doi: 10.1002/cncr.33690.
    >> Share

  106. HOPPMANN AL, Chen Y, Landier W, Hageman L, et al
    Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33760.
    >> Share

  107. SASAKI K, Kantarjian HM, Morita K, Short NJ, et al
    Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Cancer. 2021 Jun 17. doi: 10.1002/cncr.33655.
    >> Share

    May 2021
  108. NGUYEN HTK, Terao MA, Green DM, Pui CH, et al
    Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management.
    Cancer. 2021 May 25. doi: 10.1002/cncr.33609.
    >> Share

  109. BORTHAKUR G, Odenike O, Aldoss I, Rizzieri DA, et al
    A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Cancer. 2021 May 2. doi: 10.1002/cncr.33590.
    >> Share

  110. PRINTZ C
    First Person Profile: Cheryl Willman, MD: As director and CEO of the University of New Mexico Comprehensive Cancer Center, Dr. Willman has led major health equity initiatives while making pioneering discoveries in precision medicine.
    Cancer. 2021;127:1357-1358.
    >> Share

    April 2021
  111. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Sasaki K, Masarova L, et al
    Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
    Cancer. 2021 Apr 29. doi: 10.1002/cncr.33622.
    >> Share

  112. IIJIMA M, Liu W, Panetta JC, Hudson MM, et al
    Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy.
    Cancer. 2021 Apr 29. doi: 10.1002/cncr.33624.
    >> Share

  113. ALLEN OS, Kim N, Morillo J, Smith CB, et al
    Assessment of prognostic understanding, perceived goals of care, and quality of life in hospitalized patients with leukemia or multiple myeloma.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33599.
    >> Share

  114. JAMY OH, Godby R, Dhir A, Costa LJ, et al
    Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33593.
    >> Share

  115. PEMMARAJU N
    A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33594.
    >> Share

  116. MORITA K, Kantarjian HM, Sasaki K, Issa GC, et al
    Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33539.
    >> Share

  117. CALDWELL KJ, Budhraja A, Opferman JT, Pui CH, et al
    Activity of venetoclax against relapsed acute undifferentiated leukemia.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33531.
    >> Share

  118. SASAKI K, Ravandi F, Kadia TM, DiNardo CD, et al
    De novo acute myeloid leukemia: A population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.
    Cancer. 2021 Apr 5. doi: 10.1002/cncr.33458.
    >> Share

  119. BENCOMO-ALVAREZ AE, Gonzalez MA, Rubio AJ, Olivas IM, et al
    Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study.
    Cancer. 2021;127:1068-1079.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016